Drug intelligence / Profile preview

bevacizumab biosimilar BCD-021

Development stage: Phase 3
Lead developer: Biocad
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

BCD-021 is a bevacizumab biosimilar developed by Russian biotechnology company Biocad. It has demonstrated equivalence to reference bevacizumab (Avastin) in comprehensive comparability exercises including physicochemical, pharmacokinetic, and pharmacodynamic studies. Phase 3 clinical trials have shown non-inferiority to Avastin in patients with advanced non-squamous non-small cell lung cancer (NSCLC). BCD-021 was approved as a biosimilar in November 2015 by the Russian Ministry of Health.

Brand names: Avegra

Targets

VEGFA (Vascular endothelial growth factor A)

Beyond the preview

Go deeper on bevacizumab biosimilar BCD-021.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bevacizumab biosimilar BCD-021.

Explore the full profile